Safety Parameter: Adverse Events Until study termination; 3 years [clinicaltrials_resource:9f7bbbd714610f9ea8ef440af3e5fce5]
Phase 1B: To determine the MTD of E7080 in combination with carboplatin and gemcitabine as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7080. Phase II: Safety and tolerability of E7080 at the MTD determined in Phase Ib in combination with carboplatin and gemcitabine as measured by rate of adverse events by body system and grade.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety Parameter: Adverse Events Until study termination; 3 years [clinicaltrials_resource:9f7bbbd714610f9ea8ef440af3e5fce5]
Phase 1B: To determine the MTD of E7080 in combination with carboplatin and gemcitabine as determined by occurrence of dose-limiting toxicity at 3 ascending dose levels of E7080. Phase II: Safety and tolerability of E7080 at the MTD determined in Phase Ib in combination with carboplatin and gemcitabine as measured by rate of adverse events by body system and grade.
Bio2RDF identifier
9f7bbbd714610f9ea8ef440af3e5fce5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9f7bbbd714610f9ea8ef440af3e5fce5
measure [clinicaltrials_vocabulary:measure]
Safety Parameter: Adverse Events
time frame [clinicaltrials_vocabulary:time-frame]
Until study termination; 3 years
description
Phase 1B: To determine the MTD ...... ents by body system and grade.
identifier
clinicaltrials_resource:9f7bbbd714610f9ea8ef440af3e5fce5
title
Safety Parameter: Adverse Events Until study termination; 3 years
@en
type
label
Safety Parameter: Adverse Even ...... bbbd714610f9ea8ef440af3e5fce5]
@en